Clinical Trials

Title   A Randomized, Open-Label Phase 2 Study of Nanoliposomal Irinotecan (nal-IRI)-containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients with Peviously Untreated, Metastatic Pancreatic Adenocarcinoma
Description   This is an open-label, phase 2 comparative study to assess the safety, tolerability, and preliminary efficacy of nal-IRI in combination with other anticancer therapies in patients with advanced pancreatic adenocarcinoma who have not received prior chemotherapy.
IRB Number   18-086
Treatment   Oncology - Pancreatic Cancer
Status   Active
Start Date   04/25/2018
Principal Name   Moh'd Khushman MD
Contact Name   Kathleen Ollis

Email Newsletters

Connect With Us